Dicot Pharma
0.296
SEK
-4.68 %
Less than 1K followers
DICOT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-4.68%
+7.65%
+21.86%
+21.86%
+78.01%
+99.89%
-2.03%
-57.72%
-88.44%
Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug for the treatment of erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are the main desired properties. Dicot's main strategy is to continuously evaluate industrial partnerships during the development of LIB-01 to take the drug candidate to commercialization.
Read moreMarket cap
525.63M SEK
Turnover
1.63M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
29.4
2025
Interim report Q1'25
6.5
2025
General meeting '25
12.8
2025
Interim report Q2'25
All
Press releases
ShowingAll content types
Dicot Pharma AB: Dicot Pharma invites to a Q&A session on TO 6
Dicot Pharma AB: Exercise Period for Warrants TO6 in Dicot Pharma Begins Today
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools